News
Walgreens is not the only company in the US that has tried to expand beyond standard pharmacy operations. For example, CVS had tried to assist with clinical trials but closed the facility down after ...
Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.
Monte Rosa Therapeutics has dosed the first participants in the Phase I trial of the NEK7-directed molecular glue degrader (MGD), MRT-8102.
New guidelines recommended by WHO will need to be backed with funding to be implemented at scale in affected communities.
AstraZeneca's Tagrisso combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS).
Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.
Industry experts have provided insight into how oncology clinical trials can be designed for success from the outset and rendered as patient-centric as possible.
Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the company to reconsider the drug’s future. The Phase III study (NCT06400511) ...
Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) of HRS9531.
OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod to treat NCP.
AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III trials.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results